Guidance Capital Inc. Increases Stock Position in Amgen Inc. (NASDAQ:AMGN)

Guidance Capital Inc. grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,114 shares of the medical research company’s stock after acquiring an additional 98 shares during the quarter. Guidance Capital Inc.’s holdings in Amgen were worth $1,967,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Commerzbank Aktiengesellschaft FI boosted its holdings in shares of Amgen by 24.4% in the third quarter. Commerzbank Aktiengesellschaft FI now owns 58,824 shares of the medical research company’s stock worth $18,954,000 after buying an additional 11,540 shares during the last quarter. Elevated Capital Advisors LLC lifted its holdings in Amgen by 2.5% during the third quarter. Elevated Capital Advisors LLC now owns 1,539 shares of the medical research company’s stock valued at $496,000 after purchasing an additional 38 shares in the last quarter. Segment Wealth Management LLC lifted its holdings in Amgen by 5.6% during the third quarter. Segment Wealth Management LLC now owns 938 shares of the medical research company’s stock valued at $302,000 after purchasing an additional 50 shares in the last quarter. Tempus Wealth Planning LLC lifted its holdings in Amgen by 4.3% during the third quarter. Tempus Wealth Planning LLC now owns 5,518 shares of the medical research company’s stock valued at $1,778,000 after purchasing an additional 228 shares in the last quarter. Finally, Stanley Laman Group Ltd. lifted its holdings in Amgen by 2.2% during the third quarter. Stanley Laman Group Ltd. now owns 10,973 shares of the medical research company’s stock valued at $3,536,000 after purchasing an additional 237 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $305.00 price objective (down previously from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Barclays lifted their price objective on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research report on Monday, October 7th. Bank of America lifted their price objective on shares of Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. TD Cowen lifted their price objective on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research report on Monday. Finally, Oppenheimer reiterated an “outperform” rating and set a $380.00 price objective on shares of Amgen in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $332.55.

Amgen Trading Down 0.9 %

AMGN stock traded down $2.88 during mid-day trading on Wednesday, reaching $316.78. 229,171 shares of the stock traded hands, compared to its average volume of 2,431,025. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. Amgen Inc. has a one year low of $249.70 and a one year high of $346.85. The stock has a market capitalization of $169.93 billion, a PE ratio of 45.67, a PEG ratio of 2.86 and a beta of 0.61. The business has a 50-day moving average price of $325.93 and a two-hundred day moving average price of $313.11.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The firm had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.35 billion. During the same quarter last year, the firm earned $5.00 EPS. The company’s revenue was up 20.1% on a year-over-year basis. Equities research analysts expect that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were given a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 2.84%. The ex-dividend date was Friday, August 16th. Amgen’s dividend payout ratio (DPR) is 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.